Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the injection works, where it goes, and what to expect week to week
Why does it matter whether tirzepatide is intramuscular or subcutaneous?
The confusion is understandable. Many people associate injections with muscles, vaccinations at the GP surgery, vitamin B12 jabs, that sort of thing. Intramuscular injections go deep, often hurt briefly, and usually need a longer needle. Subcutaneous injections are different in almost every way.
With tirzepatide, the medicine is designed to be absorbed slowly through adipose (fatty) tissue. Delivering it into muscle would change its absorption profile and is not what the licensed method specifies. The NHS tirzepatide patient information page is clear on this: subcutaneous, not intramuscular. The pre-filled Mounjaro KwikPen reflects that, its needle is short and fine precisely because it only needs to reach just below the skin surface.
Practically, this means the injection is less physically demanding than people fear. There is no need to locate a specific muscle group, angle the needle steeply, or brace for depth. Most people describe a brief pinch at most. The technique takes a minute or two once it becomes routine, which it generally does quickly.
If you have ever self-administered insulin or another subcutaneous medicine, the process will feel familiar. If this would be your first time, the patient information leaflet supplied with each pen walks through it step by step, and our prescribers are available to answer questions about technique through aftercare.
Where exactly does each injection go, and how does rotation work?
Three sites are approved: the abdomen (at least a few centimetres from the navel), the outer thigh and the upper arm. Rotating between sites (and moving within each site from one week to the next) matters because using the exact same spot repeatedly can cause localised changes to fatty tissue over time, which may affect how the medicine is absorbed.
A simple system works well. Some people cycle through the three sites in order; others stick to one site for a few weeks then switch. The right approach is whatever the prescribing clinician and the patient information leaflet recommend for this individual. The Mounjaro KwikPen, which holds four weekly doses, makes the cadence easy to track.
Storage is straightforward: the pen lives in the fridge between doses. One thing worth keeping in mind if you order around a bank holiday or plan to travel is that the pen needs to stay within the temperature range specified in the patient information leaflet, always check that leaflet rather than relying on a general rule, since the permitted room-temperature window can be easy to misremember.
On the mechanics of the medicine itself, tirzepatide has an unusually complex molecular structure that underpins its dual-receptor action, if that side of things interests you, there is a more detailed look at the molecular weight of tirzepatide on this site.
What does 'subcutaneous' actually mean for the experience of taking tirzepatide?
Beyond the technical definition, subcutaneous delivery shapes the day-to-day experience of treatment in ways that are worth understanding before you start.
The medicine releases gradually from the fatty tissue into the bloodstream, which is why a once-weekly schedule is enough to maintain steady levels. This slow-release profile also means side effects, when they occur, tend not to arrive suddenly. The most common ones are gastrointestinal: nausea, loose stools, constipation, indigestion, or a general feeling of fullness that lingers. These are most noticeable in the first few weeks or after a dose increase, and for many people they settle without needing to change the dose. The NICE technology appraisal of tirzepatide (TA1026) draws on a body of evidence showing that most participants in the clinical programme continued treatment through the initial GI adjustment period.
More serious symptoms (severe stomach pain that extends to the back, persistent vomiting preventing adequate hydration, or signs of an allergic reaction) need prompt medical attention. Any suspected side effect can be reported through the MHRA's Yellow Card scheme. That reporting scheme is part of why Black Triangle medicines like tirzepatide build a richer post-market safety record quickly.
Beyond GI effects, some people notice fatigue, mild headache or dizziness, particularly early in treatment. Injection sites are usually fine, though mild redness or tenderness can occur; rotating sites helps with that. The broader picture of how tirzepatide affects the cardiovascular system is a growing area of research, and there is a dedicated page covering tirzepatide and heart health for anyone interested in that evidence.
Who can be assessed for tirzepatide, and what does the clinical process look like?
Tirzepatide (Mounjaro) holds a UK licence for weight management in adults with a BMI of 30 or above, or from 27 upwards when at least one weight-related condition is present, conditions such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. BMI thresholds are adjusted downward for some ethnic backgrounds under current UK guidance. Meeting those numbers is a starting point, not a guarantee: a prescriber reviews the full clinical picture before approving treatment.
Private assessment through a regulated online pharmacy removes the NHS waiting list from the equation. If you are weighing up what Mounjaro costs privately, the honest answer is that legitimate treatment includes the prescription and clinical oversight, not just the pen. That context matters when comparing prices across providers.
At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, not processed by an algorithm. Identity and weight are verified before treatment is issued, and aftercare runs seven days a week. For anyone who wants to understand our broader approach before starting, the Mounjaro overview page covers the full picture, or you can read about our clinical team directly on the prescriber profile page.
If you are ready to see whether tirzepatide is clinically suitable for you, start your free consultation and a prescriber will review your answers the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.